New Products

Sep 21, 2017

PierianDx Clinical Genomicist Workspace

PierianDx said that its Clinical Genomicist Workspace genomics workflow and analysis software now supports clinical microarray technology (CMA). CMA enhancements within CGW include workflow integration to submit processed microarray results from a batch of samples to generation of a templated report without user intervention; the ability to review, sort, and filter copy number variants (CNV) as well as loss of heterozygosity (LOH) segments and associated quality information; the ability to set laboratory-specific validation filters for CNV and LOH segments as well as specific panel- and case-specific filters; clinical interpretations that are automatically inferred in patient cases for review and editing; and an updated knowledgebase that includes published literature for articles that mention cytogenetic positions, genes, and phenotypes associated with a patient case.

Sep 20, 2017

Blueprint Genetics Whole Exome Sequencing

Blueprint Genetics is now offering whole-exome sequencing to customers in the US. The assay has a minimum mean coverage of 100-fold. On average, 98.9 percent of gene-coding regions, captured with Agilent SureSelect V6, are covered at least 15-fold. The company confirms all clinically relevant variants by Sanger sequencing and its interpretation team includes clinical experts. Turnaround time for the assay, which comes in different versions, is six to nine weeks.

Sep 19, 2017

ARUP Laboratories/IDbyDNA Explify Respiratory

ARUP Laboratories and IDbyDNA have launched Explify Respiratory, a next-generation sequencing-based test for respiratory infections. Explify Respiratory detects more than 200 common and rare bacterial, fungal, and viral respiratory pathogens with a single test. It is powered by IDbyDNA's Taxonomer software, a DNA search engine that can rapidly identify any organism by its genetic material. The test is the first in a line of tests that ARUP Labs and IDbyDNA plan to launch as part of a previously announced strategic partnership to develop and commercialize infectious disease testing using metagenomics.

Sep 18, 2017

Horizon Discovery CRISPRi and CRISPRa Screening Services

Horizon Discovery announced that it has expanded its functional genomic screening portfolio to include CRISPRi (interference) and CRISPRa (activation) screening services. Horizon's CRISPRi/CRISPRa screening platform substantially broadens the range of possible studies through the capacity to reduce or increase, rather than completely eliminating gene expression, the company said. This enables customers to address critical gaps in target ID and validation as they work to develop novel and more effective drug therapies. The screening capabilities are based on the company's highly optimised CRISPR knockout screening platform. Horizon has also developed an enhanced solution that combines both CRISPRi and CRISPRa screening. This combined solution can reveal 'switch'-like genes that display opposing effects when activated or inhibited in the presence of the drug of interest.

Sep 18, 2017

Evosep One

Evosep introduced Evosep One, an optimized separation technology for mass spectrometers for large cohort experiments. Evosep One is designed for fast and robust separation of omics samples while enabling 24-hour operation at 200 samples a day. The product reduces cross-contamination through the use of disposable tips, and high flow rate during autosampler washing steps. According to the company, Evosep One also improves up time and reliability through partial elution that leaves impurities from each sample on the disposable tips that act as pre-columns, and from low-pressure elution and gradient formation that causes less wear and tear.

Sep 14, 2017

Qnostics ME Evaluation Panel

Qnostics launched the ME Evaluation Panel for meningitis/encephalitis evaluation. It consists of 14 controls for the qualitative detection of bacterial, viral, and fungal targets, including Neisseria meningitidis, Haemophilus influenzae, Escherichia coli K1, and others. The panel can be used to independently monitor each target and all phases of the testing process, Qnostics said, adding it was designed with known performance on the BioFire FilmArray platform. 

Sep 13, 2017

Phosphorous Ophthalmology, Drug Response Test

Computational genomics firm Phosphorus launched a test for inherited conditions associated with vision loss and blindness, and a pharmacogenomic test to assess the efficacy of various drugs based on their genetic makeup. The ophthalmology genetic test covers retinal disorders, cataracts, glaucoma, and corneal dystrophy. The drug response test covers cardiology, psychiatry, oncology, pain management, neurology, immunology. gastroenterology, repiratory, infectious disease, and others. 

Sep 13, 2017

BC Platforms BC|RQUEST

BC Platforms has introduced BC|RQUEST, a system for analyzing and viewing aggregated genomic and clinical data from multiple biobanks. The platform will be available to members of the Open Biobank Research Enhancement Alliance (OBREA), which Basel, Switzerland-based BC Platforms created.

Sep 13, 2017

Variantyx Unity

Variantyx launched the Variantyx Unity test, a genomic diagnostic test that identifies small sequence changes, structural variants, trinucleotide repeat expansions, and mitochondrial variants from a single DNA sample. The test uses whole-genome seuqncing data analyzed by the firm's Genomic Intelligence platform, and eliminates the need for multiple sequential tests, the firm said. 

Sep 12, 2017

DiaSorin Molecular Simplexa C. difficile Direct Assay

DiaSorin Molecular has launched the Simplexa C. difficile Direct Assay in the US. The assay aids in the diagnosis of infection by detecting the C. difficile toxin B gene in liquid or unformed stool samples, and had been available outside the US since November. The US Food and Drug Administration cleared the test in February

Sep 12, 2017

Benson Hill Biosystems CRISPR 3.0

Benson Hill Biosystems has launched CRISPR 3.0, a novel family of Cms1 nucleases, as part of its suite of genomics tools to accelerate crop performance improvements. The CRISPR 3.0 portfolio of nucleases demonstrate a shorter length than many other widely-used nucleases, enabling easier delivery, the firm said.

Sep 12, 2017

Bio-Rad ZDC Multiplex RT-PCR assay

Bio-Rad Laboratories has launched the ZDC Multiplex RT-PCR assay, a research-use only tool for the simultaneous screening of sample for Zika, dengue, and chikungunya arbovirus RNAs. The assay comes with all controls that researchers need to validate results internally. The RT-PCR kit was launched outside the US earlier this year. 

Sep 12, 2017

Becton Dickinson Rhapsody Platform Assay

Becton Dickinson announced the launch of BD Rhapsody, a platform for single cell RNA analysis. According to BD, the system consists of reagents, instruments, and software for targeted gene expression analysis of ten of thousands of individual cells. The platform will also expand beyond RNA expression to include protein detection. BD will offer both application-specific targeted panels and enable customers to design their own custom, targeted panels.

Sep 11, 2017

Tecan Resolvex for LC-MS Sample Prep

Tecan has launched the automated Resolvex A200 positive pressure workstation for LC-MS sample prep. The platform offers unattended positive pressure solid phase extraction, providing increased walkaway times for LC-MS sample preparation workflows. Eight-channel dispensing delivers a three-fold increase in speed compared to single-channel dispensing, and the touchscreen control enables straightforward integration into laboratory protocols. The system is compatible with Tecan's range of 96-well plate and column format smart consumables, including narrow bore extraction columns that transform an extraction column into a reaction vessel.

Sep 07, 2017

Eurofins Genoma GeneSafe

Eurofins Genoma has introduced GeneSafe, a non-invasive prenatal test that screens for both de novo and inherited single-gene disorders. Current commercial NIPTs only screen for aneuploidies and microdeletions, the firm said. GeneSafe identifies fetal conditions that could be missed by traditional prenatal testing, detecting more than 40 severe genetic disorders that may occur in the absence of a family history of the condition. The company said it also detects disorders with an increased prevalence associated with advanced paternal age. The test requires a small blood sample and has a turnaround time of 10 days. It works as a complementary screen to traditional NIPT, providing a more complete picture of the risk of a pregnancy being affected by a genetic disorder, the company noted.

Sep 07, 2017

Myriad Genetics riskScore

Myriad Genetics has launched riskScore, which employs a proprietary algorithm combining analysis of 80 SNPs and patients' personal and family history of cancer to determine a woman's risk of breast cancer. Results from this test will be reported alongside Myriad's myRisk Hereditary Cancer test, a 28-gene panel that gauges patients' risk for for eight cancers. RiskScore will help guide decisions for asymptomatic patients who get negative myRisk results, providing definitive answers to the 90 percent of patients testing negative for hereditary cancer genes, the company noted. Myriad has completed two validation studies in patients of European descent that it will present at upcoming conferences.

Sep 07, 2017

Ranomics VariantFind DNA Library Synthesis

Ranomics, a Toronto-based biotechnology firm, has launched VariantFind, a proprietary platform for creating DNA libraries. VariantFind uses multiplexing technology to incorporate a large number of mutagenic oligonucleotides into a single series of PCR reactions to create high-quality and cost-effective variant libraries for use in protein engineering, synthetic biology, and agriculture, the company said. The resulting libraries can be easily integrated into different workflows, Ranomics added.

Sep 07, 2017

Intermountain Precision Genomics RxMatch

Intermountain Precision Genomics Core Laboratory launched RxMatch, a new service to enable physicians to implement personalized medicine when prescribing medications. The RxMatch Antidepressant Panel, launched Sept. 5 as part of the new service, will allow physicians to use patients' genomics to find the right antidepressant. The RxMatch Antidepressant Panel will be powered by CNSDose, a company that will provide decision support to Intermountain based on its knowledge of liver and blood-brain-barrier metabolism of antidepressant medications.

Sep 06, 2017

Bionano Genomics Inversion Detection Algorithms

Bionano Genomics has released updated algorithms, analysis tools, and visualization software for the genome-wide detection of inversions. Previous releases have focused on the automated calling of large insertions, deletions, and translocations. Bionano said its genome mapping platform Saphyr detects 90 percent of heterozygous insertions and deletions larger than 1 kilobase pairs and 98 percent of all translocations. The new release focuses on mapping the order and orientation of the genome by greatly improving the ability to identify inversions of 30 kbp up to megabases in size. The new algorithms have 98 percent sensitivity to pick up inversions larger than 50 kbp throughout the genome. All of Bionano's structural variants are reported in dbVar-compliant VCF format.

Sep 06, 2017

Cynvenio Biosystems PD-L2 Expression Test

Cynvenio Biosystems launched its PD-L2 expression test, a research-use-only test that measures PD-L2 expression in circulating tumor cells, enabling specific profiling and monitoring of PD-L2 expression in cancer cells from a simple blood draw.

Sep 05, 2017

Biocept NRAS Liquid Biopsy Test

Biocept has launched a new Target Selector liqud biopsy assay for mutations in the NRAS oncogene. According to the company, the NRAS mutations targeted by the test are associated with multiple cancer types such as metastatic melanoma, colorectal and lung cancer. The new test, like Biocept's other clinical assays, is run in its CLIA-certified San Diego lab. The new product brings the company's total number of Target Selector tests to 15.

Sep 01, 2017

Thermo Fisher Immune Repertoire, Liquid Biopsy NGS Assays

Thermo Fisher has launched the Ion AmpliSeq Immune Repertoire Assay Plus, TCR Beta, a research-use-only, multi-target sequencing panel for immuno-oncology applications. The new panel can be run from sample to analysis in as little as 48 hours, with up to 400-bp read-length amplicons for complete characterization of CDR1, CDR2, and CDR3, according to the company's website.

The company also launched the Ion Torrent Oncomine Lung Cell-Free Total Nucleic Acid Research Asssay, which includes fusion markers associated with lung cancer, including ALK, RET, and ROS1, in addition to DNA, RNA hotspots, copy number variants and MET exon 14 skipping. Thermo Fisher also updated the Ion Torrent Oncomine Breast cfDNA Research Assay. Version 2 now includes new CNVs, more complete coverage of key tumor suppressor gene TP53 and additional SNVs and indels. From a single tube of blood, researchers can use the assays to detect primary tumor drivers and mutations known to cause therapeutic resistance down to 0.1 percent limit of detection, the company said.

Thermo Fisher announced the new products in conjunction with the announcement that it has formed an Immuno-Oncology Consortium to drive adoption of next-generation sequencing (NGS) clinical research panels for the identification of predictive and prognostic biomarkers associated with cancer immunotherapy.

Aug 29, 2017

Dolomite Bio Single Nucleus RNA-seq Chip

Dolomite Bio plans to launch this fall a chip for the single-nucleus RNA sequencing technique, DroNc-seq, developed by researchers at the Broad Institute. The new chip is based on the company's established single-cell RNA-seq chip and is designed to produce smaller droplets to enable profiling of thousands of nuclei. The chip is compatible with Dolomite Bio's Single Cell RNA-seq System and has been optimized for single nuclei. 

Aug 24, 2017

Cynvenio Biosystems ClearID HER2 Expression Test

Cynvenio Biosystems launched its ClearID HER2 Expression Test. The liquid biopsy test allows doctors to perform real-time monitoring and analysis of HER2 levels in patients with a normal blood draw. It leverages Cynvenio's liquid biopsy technology and uses antibodies against EpCAM, TROP2, HER2, and EGFR. The test has a turnaround time of three to seven days and is processed by Cynvenio's CLIA/CAP laboratory in California.

Aug 22, 2017

Sunquest Mitogen LIMS and Genetic Analysis Software

Sunquest Information Systems has released Sunquest Mitogen, a new laboratory information management system and genetic analysis software platform to support molecular diagnostics and precision medicine. Mitogen, based in part on technology Sunquest acquired when it bought GeneInsight and UniConnect in 2016, is meant to help both wet and dry labs move into next-generation sequencing. 

Pages

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.